Phase 2CompletedINTERVENTIONAL
Efficacy and Safety of IL-11 in DDAVP Unresponsive
ClinicalTrials.gov · NCT00994929 · Registry updated: 2016-03-02
- Condition / research focus
- Hemophilia A; Von Willebrand Disease
- Sponsor
- University of Pittsburgh
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2010-01. Completion: 2012-04 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Neumega (Oprelvekin, Interleukin 11, IL-11) (biological) — also listed as: Interleukin-11, IL-11, Oprelvekin
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported